(Total Views: 328)
Posted On: 10/21/2022 10:35:52 AM
Post# of 63
$MTNB News Article - Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90% https://marketwirenews.com/news-releases/mati...93348.html
(1)
(0)
My Twitter: WhyteStocks
